# Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

> **NCT00050167** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 603 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00050167
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2008-07
- **Final completion:** 2011-08
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2011-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050167, "Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00050167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*